A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Subjects With Elevated LDL-C.
Phase of Trial: Phase I
Latest Information Update: 15 Aug 2013
At a glance
- Drugs Frovocimab (Primary) ; Frovocimab (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Feb 2013 Planned end date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.